NEW YORK, April 29, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, other diseases of the central nervous system (CNS) and various types of cancer, today announced the findings of a research study published in the current issue of peer-reviewed scientific journal Brain. For the first time, scientific data shows that a sigma-1 receptor (S1R) agonist produces functional neurorestoration in animal models of Parkinson's disease (PD). Anavex is encouraged by the report because its results point to the potential for the Company's S1R drug candidates ANAVEX 2-73, ANAVEX 3-71 (AF710B) and ANAVEX 1-41 of being disease-modifying treatments for Parkinson's disease.
Help employers find you! Check out all the jobs and post your resume.
